FIGURE 1.

Effect of SARS‐CoV‐2 vaccination on the induction of nasal neutralizing antibodies. A‐B, Percentage of patients with SARS‐CoV‐2 neutralizing antibodies (A) and ACE2 binding inhibition rates (B) in nasal secretions prior and post‐vaccination with BNT162b2 and ChAdOx1. (C‐E), Percentage of patients with SARS‐CoV‐2 NAbs (C, E) and ACE2 binding inhibition rates (D, F) post‐vaccination in nasal secretions of patients respective to prior COVID‐19 (C, D) and to allergy to aeroallergens (E,F). Asterisks indicate statistical significance by two‐way repeated‐measures ANOVA followed by Sidak's multiple comparisons test for B and by ordinary two‐way ANOVA with Tukey's multiple comparisons test for D and F. *p < 0.05, **p < 0.001, ***p < 0.0002, ****p < 0.0001